Mode
Text Size
Log in / Sign up
Phase 3 N=379 Randomized Treatment

Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility

Infertility, Female

Enrolled (actual)
379
Serious AEs
6.6%
Results posted
Mar 2021
Primary outcome: Primary: Rate of Good Birth Outcomes — 23; 29 Participants — p=0.404

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Caloric Restriction (Other); Orlistat (Drug); Moderate physical activity (Other)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Yale University
Primary completion
Nov 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate of Good Birth Outcomes
23; 29 0.404
SECONDARY
Live Birth Rate
38; 42
SECONDARY
Time to Pregnancy in Days
160; 163
SECONDARY
Pregnancy Loss Rate
24; 14
SECONDARY
Multiple Pregnancy Rate
7; 3
SECONDARY
Birth Weight in Grams
3217.7; 3189.3
SECONDARY
Mode of Delivery-Cesarean Section
19; 23

Summary

A two-arm, multicenter, prospective, randomized clinical trial of a lifestyle modification program with tracked increased physical activity and weight loss (intensive) compared to recommendations to tracking of increased physical activity alone with weight maintenance (standard) in women with obesity and unexplained infertility. This 16 week period of lifestyle modification will be followed by an open label empiric infertility treatment regimen consisting of three cycles of ovarian stimulation with oral medication (clomiphene citrate (CC)), triggering of ovulation with human chorionic gonadotropin (hCG) and intrauterine insemination (IUI).

Eligibility Criteria

Inclusion Criteria

  • Women ≥18 to ≤ 40 years of age, with one or more years infertility history, desirous of conceiving, regularly ovulating (defined as 9 or more menses per year), at initiation of participation.
  • BMI ≥ 30 kg/m2.
  • Normal uterine cavity and at least one open fallopian tube confirmed by hysterosalpingography (HSG), sonohysterography (SHG), or laparoscopy/hysteroscopy in the last three years preceding enrollment into the study. An uncomplicated intrauterine non-IVF pregnancy and uncomplicated delivery and postpartum course resulting in live birth within the last three years will also serve as sufficient evidence of a patent tube and normal uterine cavity as long as the subject did not have, during the pregnancy or subsequently, risk factors for Asherman's syndrome or serious pelvic infection or other disorder leading to an increased suspicion for intrauterine abnormality or tubal occlusion.
  • Evidence of ovarian function/reserve as assessed by menstrual cycle day 3 (+/-2 days) FSH ≤10 IU/L with estradiol ≤ 70 pg/mL OR AMH ≥ 1 ng/mL within one year prior to study initiation.
  • Normal or corrected thyroid function within one year of study initiation.
  • Normal or corrected prolactin level within one year of study initiation.
  • In general good health, not taking any medications which could interfere with the study (e.g., FSH, insulin sensitizers).
  • Ability to have inseminations following hCG administration.
  • Male partner with total motile sperm in the ejaculate of at least 5 million sperm, within one year of study initiation.
  • Able to comply with intercourse instructions and collection of semen for insemination.

Exclusion Criteria

  • Currently pregnant or successful pregnancies within 12 months of initiating participation. Clinical intrauterine miscarriages prior to initiating participation, within ASRM guidelines: subjects over 35 must wait six months, while subjects under 35 must wait 12 months. No exclusion for biochemical pregnancies.
  • Undiagnosed abnormal uterine bleeding.
  • Suspicious ovarian mass.
  • Subjects on oral contraceptives, depo-progestins, or hormonal implants (including Implanon). A two month washout period will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive methods or implants, especially when the implants are still in place. A one-month washout will be required for patients taking oral cyclic progestins.
  • Known 21-hydroxylase deficiency or other enzyme defect causing congenital adrenal hyperplasia.
  • Type I or Type II diabetes mellitus, or if receiving antidiabetic medications.
  • Known significant anemia (Hemoglobin 2 times normal, or total bilirubin >2.5 mg/dL).
  • Known Renal disease (defined as BUN >30 mg/dL or serum creatinine > 1.4 mg/dL).
  • History of, or suspected cervical carcinoma, endometrial carcinoma or breast carcinoma.
  • History of alcohol abuse (defined as >14 drinks/week) or binge drinking of ≥ 6 drinks at one time).
  • Known Cushing's disease.
  • Known or suspected adrenal or ovarian androgen secreting tumors.
  • Allergy or contraindication to the treatment medications: CC or hCG.
  • Couples with previous sterilization procedures (e.g. vasectomy, tubal ligation) whether or not it has been reversed.
  • Subjects with untreated poorly controlled hypertension defined as a systolic blood pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures at least 60 minutes apart.
  • Subjects who have undergone a bariatric surgery procedure in the past or are in a period of acute weight loss (defined as a weight loss of greater than 5 kgs in the last 6 months).
  • Known moderate or severe endometriosis.
  • Anovulation or oligo-ovulation including hypothalamic amenorrhea, polycystic ovary syndrome, etc.
  • Donated semen.
  • Couples in which either partner is legally married to someone else.
  • Medical conditions that are contraindications to pregnancy.
  • Pres
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02432209). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search